Bristol-Myers Squibb and Concerto HealthAI Announce Strategic...
Summary
“This strategic agreement with Concerto HealthAI reinforces our commitment to pursue data science to accelerate disease insights, advance novel study concepts & achieve precision in treatment, to improve patient outcomes.” - Conklin, SVP & Head of Business Insights & Analytics, Bristol-Myers Squibb BOSTON (PRWEB)March 28, 2019 Bristol-Myers Squibb and Concerto HealthAI, a market leader in oncology-specific Real-World Data (RWD) and advanced Artificial Intelligence (AI)-enabled insight solutions for Real-World Evidence (RWE) generation, today announced a multi-year strategic agreement that will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials, enable robust protocol design and generate insights for precision treatment and improved patient outcomes. “Concerto HealthAI’s singular mission,” said Dr. Elton “is to partner with leading medical societies, healthcare providers and life science companies to bring together data, technology and talent to enable new RWE insights and improve the use and broaden the beneficial impact of cancer therapies for patients. CancerLinQ® is developed and operated by CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology (ASCO). Concerto HealthAI is a technology leader in definitive Real-World Data (RWD), Precision Evidence and AI solutions for oncology.